RT Journal Article
SR Electronic
T1 Changes in life expectancy and life span equality during the COVID-19 epidemic in Japan up to 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.18.24306049
DO 10.1101/2024.04.18.24306049
A1 Okada, Yuta
A1 Nishiura, Hiroshi
YR 2024
UL http://medrxiv.org/content/early/2024/04/19/2024.04.18.24306049.abstract
AB Objectives To evaluate the impact of COVID-19 on life expectancy in Japan through demographic analyses.Methods We evaluated the relationship between the life expectancy gap from 2020–21 and 2021–22 and COVID-19 epidemic size at prefectural level. We also conducted age- and cause-specific decomposition of life expectancy change. Trends in life span equality from 2000–22 were evaluated at the national level.Results Prefectural analysis of 2021–22 life expectancy change and annual perpopulation COVID-19 cases, person-days in intensive care, and reported COVID-19 deaths showed no significant correlations, unlike our analysis from 2020–21. However, decomposition analysis revealed substantial life expectancy shortening attributable to the population over 35 years old. It also showed large increases in causes of death such as cardiovascular or respiratory disorders as well as COVID-19. Whole-population life span equality declined in 2020 but increased in 2021 and 2022 despite the shorter life expectancy.Conclusions Discrepancy between life expectancy change and COVID-19 statistics in 2022 suggests the growing ascertainment bias of COVID-19. The increased contribution of cardiovascular disorders to life expectancy shortening is an alarming sign for the future. Life span equality changes in 2021 and 2022 can probably be attributed to increased mortality among older people.HighlightsLife expectancy change was not correlated with COVID-19 epidemic activity in 2022Older people made the biggest contribution to shorter life expectancyCardiovascular disorders contributed substantially to shortening of life expectancyLife span equality increased in 2021 and 2022 despite shorter life expectancyCompeting Interest StatementThe authors have declared no competing interest.Funding StatementY.O. received funding from the SECOM Science and Technology Foundation. H.N. received funding from Health and Labour Sciences Research Grants (grant numbers 20CA2024, 21HB1002, 21HA2016, and 23HA2005), the Japan Agency for Medical Research and Development (grant numbers JP23fk0108612 and JP23fk0108685), JSPS KAKENHI (grant numbers 21H03198 and 22K19670), the Environment Research and Technology Development Fund (grant number JPMEERF20S11804) of the Environmental Restoration and Conservation Agency of Japan, Kao Health Science Research, the Daikin GAP Fund of Kyoto University, the Japan Science and Technology Agency SICORP program (grant numbers JPMJSC20U3 and JPMJSC2105), and the RISTEX program for Science, Technology, and Innovation Policy (grant number JPMJRS22B4). The funders had no role in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in supplementary materials https://www.mhlw.go.jp/stf/seisakunitsuite/newpage_00023.html https://www.fdma.go.jp/disaster/coronavirus/post-1.html https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00432.html https://www.ipss.go.jp/p-toukei/JMD/index-en.asp https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&cycle_facet=tclass1&tclass4val=0 https://covid19.mhlw.go.jp/en/ https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html https://unstats.un.org/unsd/demographic-social/crvs/documents/2023-completeness.xlsx